Nutriband Inc (NASDAQ:NTRB) — Market Cap & Net Worth
Market Cap & Net Worth: Nutriband Inc (NTRB)
Nutriband Inc (NASDAQ:NTRB) has a market capitalization of $47.00 Million ($47.00 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22116 globally and #4671 in its home market, demonstrating a -3.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nutriband Inc's stock price $3.86 by its total outstanding shares 12174883 (12.17 Million). Analyse Nutriband Inc (NTRB) cash flow conversion to see how efficiently the company converts income to cash.
Nutriband Inc Market Cap History: 2017 to 2026
Nutriband Inc's market capitalization history from 2017 to 2026. Data shows change from $68.88 Million to $47.00 Million (-4.44% CAGR).
Index Memberships
Nutriband Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #638 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2121 of 3165 |
Weight: Nutriband Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nutriband Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nutriband Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
25.83x
Nutriband Inc's market cap is 25.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $146.10 Million | $245.28K | -$3.33 Million | 595.63x | N/A |
| 2020 | $156.53 Million | $370.65K | -$2.80 Million | 422.33x | N/A |
| 2021 | $105.19 Million | $943.70K | -$3.21 Million | 111.47x | N/A |
| 2022 | $43.89 Million | $1.42 Million | -$8.42 Million | 30.86x | N/A |
| 2023 | $28.25 Million | $2.08 Million | -$4.81 Million | 13.58x | N/A |
| 2024 | $57.34 Million | $2.09 Million | -$5.49 Million | 27.50x | N/A |
| 2025 | $55.27 Million | $2.14 Million | -$10.48 Million | 25.83x | N/A |
Competitor Companies of NTRB by Market Capitalization
Companies near Nutriband Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Nutriband Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Nutriband Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Nutriband Inc's market cap moved from $68.88 Million to $ 47.00 Million, with a yearly change of -4.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $47.00 Million | -14.98% |
| 2025 | $55.27 Million | -3.61% |
| 2024 | $57.34 Million | +103.02% |
| 2023 | $28.25 Million | -35.64% |
| 2022 | $43.89 Million | -58.28% |
| 2021 | $105.19 Million | -32.80% |
| 2020 | $156.53 Million | +7.14% |
| 2019 | $146.10 Million | -59.06% |
| 2018 | $356.90 Million | +418.18% |
| 2017 | $68.88 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Nutriband Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.00 Million USD |
| MoneyControl | $47.00 Million USD |
| MarketWatch | $47.00 Million USD |
| marketcap.company | $47.00 Million USD |
| Reuters | $47.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more